Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design

2021 ◽  
pp. 101281
Author(s):  
Pierpaolo Pellicori ◽  
Muthiah Vaduganathan ◽  
João Pedro Ferreira ◽  
Faiez Zannad ◽  
Arun J. Sanyal
Keyword(s):  
Cardiovascular Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Cross Talk ◽  
Fatty Liver Disease ◽  
Trial Design ◽  
Future Trial ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Liver disease

2019 ◽  
pp. 367-384
Author(s):  
Nina Vodošek Hojs ◽  
Aftab Ala ◽  
Debasish Banerjee
Keyword(s):  
Cardiovascular Disease ◽  
Liver Disease ◽  
Hepatitis C ◽  
Fatty Liver ◽  
Viral Hepatitis ◽  
Liver Dysfunction ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Cardiovascular disease in patients with liver disease, previously uncommon, is rising because of an increasing incidence of non-alcoholic fatty liver disease and better survival of patients with viral hepatitis, particularly hepatitis C. Liver dysfunction alters the pharmacokinetics and pharmacodynamics of many drugs, and hence careful use and dose adjustments are necessary. This chapter describes common cardiovascular conditions and the pharmacotherapy in patients with different liver diseases.

Sign in / Sign up

Export Citation Format

Share Document